Browse AMR Mutations
Explore antimicrobial resistance mutations from the literature
Explore antimicrobial resistance mutations from the literature
Overview
Adding Insult to Injury: Mechanistic Basis for How AmpC Mutations Allow Pseudomonas aeruginosa To Accelerate Cephalosporin Hydrolysis and Evade Avibactam.
Mutations in ampC lead to reduced avibactam inhibition and increased resistance to ceftolozane and ceftazidime.
A 2.5-years within-patient evolution of a Pseudomonas aeruginosa with in vivo acquisition of ceftolozane-tazobactam and ceftazidime-avibactam resistance upon treatment.
The G183D mutation in ampC leads to resistance to ceftolozane-tazobactam and ceftazidime-avibactam.
Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling.
In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.
mutations in ampC are associated with treatment-emergent resistance to ceftolozane-tazobactam
Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?
Mutations in ampC were the primary mechanism of TOL-TAZ resistance.
Integrated Genome-Wide Analysis of an Isogenic Pair of Pseudomonas aeruginosa Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam.
Non-synonymous mutation in bla PDC-35 gene
Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa.
Mutations in the Ω-loop of ampC lead to increased resistance to ceftolozane/tazobactam and decreased resistance to imipenem.
No comments yet. Be the first to comment!
© 2026 ResLit. Data sourced from PubMed literature analysis.
Built for antimicrobial resistance research